Company intelligence / Profile preview

Enikam

Ownership: Private
Development stage: Other

Overview

Enikam develops and markets innovative cosmetic and pharmaceutical products based on stabilized active oxygen compounds. Their products are designed to support the health of skin, nails, and the oral cavity by promoting cell nourishment and regeneration. The company claims a novel mechanism of action distinct from antibiotics or corticosteroids. Clinical results are not detailed publicly.

Therapeutic areas: DermatologyOther
Modalities: Small moleculeBiologic (active oxygen compounds)
Industry: Biotech

Drug pipeline

1 asset

oroxid

Beyond the preview

Go deeper on Enikam.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enikam.

Explore the full profile